GENERAL CLINICAL RESEARCH CENTER

德克萨斯大学健康科学临床研究中心 中心和赫尔曼医院为临床提供独特的环境 调查。德克萨斯大学医学院和德克萨斯大学M.D.安德森大学的教职员工 癌症中心认识到拥有这一功能的优势和重要性 多学科设施，提供对 实验条件，对生物现象的准确监测，以及 妥善收集和处理有价值的标本。主要研究 这些地区将包括： 1.人巨噬细胞对纤维化反应的功能分析 微粒。 2.177-Lu-CC49联合α-干扰素治疗晚期非小细胞肺癌 或者复发的卵巢癌。 3.阐明家族性遗传病的遗传分子因素 主动脉瘤。 4.在体外用rIFN-γ和rIL-2进行腹膜腔内注射 活化的肿瘤浸润性淋巴细胞在免疫治疗中的扩增 上皮性卵巢癌。 5.阐明HIV对血友病生长发育的影响 儿童、青少年和年轻人。 6.微小隐孢子虫感染性机制的阐明 对成年人类来说。 7.弥漫性浸润性淋巴细胞增多综合征的特征 HIV感染患者的DILS及其预后。 8.人类的基因治疗和安全修饰的逆转录病毒的使用 引入化疗耐药序列用于化疗期间的化学保护 卵巢癌的治疗 在我们的临床研究中心(CRC)，我们希望进行有意义的 阐明人类致病基本机制的临床研究 疾病导致了治疗方法的改进。我们希望解决重要的问题 影响儿童和成人的疾病和疾病过程 期待我们的研究提供的新见解将有助于 以根除和预防严重的医疗问题。我们的CRC将 结合德克萨斯大学医学院的临床研究工作 学校和德克萨斯大学安德森癌症中心 休斯敦。我们期望这次联合研究工作将带来新的成果。 基于机制的疗法，有助于治愈并最终预防选定的 医学疾病。

The Clinical Research Center at the University of Texas Health Science Center and Hermann Hospital provides a unique environment for clinical investigation. The faculty of the UT Medical School and UT M.D. Anderson Cancer Center appreciate the advantage and importance of having this multidisciplinary facility which provides meticulous control of experimental conditions, accurate monitoring of biologic phenomena, and proper collection and handling of valuable specimens. Major research areas will include: 1. Analysis of human macrophage function in response to fibrogenic particulates. 2. Use of 177-Lu-CC49 plus alpha interferon in patients with advanced or recurrent ovarian cancer. 3. Elucidation of genetic molecular factors responsible for familial aortic aneurysms. 4. Intraperitoneal priming with rIFNgamma followed by rlL-2 for ex vivo expansion of activated tumor infiltrating lymphocytes in immunotherapy of epithelial ovarian cancer. 5. Elucidation of effects of HIV on growth and development of hemophilic children, adolescents, and young adults. 6. Elucidation of mechanisms of infectivity of Cryptosporidium parvum for adult humans. 7. Characterization of diffuse infiltrating lymphocytosis syndrome (DILS) and its prognosis in patients with HIV infection. 8. Gene therapy in humans and the use of safety-modified retroviruses to introduce chemotherapy resistance sequences for chemoprotection during the therapy of ovarian cancer In our Clinical Research Center (CRC), we wish to conduct meaningful clinical research that elucidate basic mechanisms responsible for human disease leading to improved therapies. We wish to address important diseases and disease processes that affect children and adults with the expectation that the new insights our research provides will contribute to eradication and prevention of serious medical problems. Our CRC will combine clinical research efforts at the University of Texas Medical School and the University of Texas M.D. Anderson Cancer Center at Houston. We anticipate that this combined research effort will lead o new mechanism based therapies that help cure and ultimately prevent selected medical diseases.